Time-to-disease progression and myeloma progression events in the cohort of 427 patients with SMM diagnosed between 2014 and 2023. (A) Time-to-progression to symptomatic myeloma in patients with SMM and non-immunoglobulin M (IgM) MGUS diagnosed over the same time period. (B) Time-to-progression to symptomatic myeloma in patients with SMM according to 20/2/20 risk category and non-IgM MGUS diagnosed over the same time period. (C) Patterns of disease progression according to risk category per 20/2/20 model. (D) UpSet plot of disease progression events. Hb, hemoglobin; int., intermediate.